XORTX Therapeutics (XRTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$1.7M

Net income growth (year over year)

−135.58%

Net margin

—

Return on equity

−99.24%

EPS (trailing twelve months)

−$2.58

Book value per share

$3.18

P/E (trailing twelve months)

—

Price to book

0.54

Debt to assets

10.99%

Payout ratio

—

Dividend yield

—

Company profile

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

• How do I buy stock in XORTX Therapeutics (XRTX)?

  XRTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.